#USA #San Mateo #Talphera #Nafamostat #Niyad®

Talphera to Host Virtual Investor and Analyst Event

Talphera, Inc. (Nasdaq: TLPH), a leader in the specialty pharmaceutical sector focused on innovative treatment solutions, is scheduled to host a virtual investor and analyst event on March 23, 2026, at 11:00 AM ET. This event features distinguished speakers, Dr. Blaithin McMahon from the Medical University of South Carolina and Dr. Joao Teixeira from the University of New Mexico, both principal investigators involved in the NEPHRO CRRT study.

The focus of the discussion will be the therapeutic innovation surrounding Niyad®, a lyophilized formulation of nafamostat, which is being evaluated for its effectiveness in Continuous Renal Replacement Therapy (CRRT). The two experts will share insights about their experiences with CRRT and the anticoagulants currently in use.

Insights into CRRT and Anticoagulation Needs

CRRT is a critical procedure used in intensive care settings, and the anticoagulants applied during this treatment are vital for patient safety. The presentation will dive into why there is an urgent requirement for advancements in anticoagulation strategies within CRRT, particularly emphasizing Talphera's nafamostat. This compound, notable for its broad-spectrum serine protease inhibition properties, has a history of safe usage in Japan and South Korea, yet remains largely underutilized in the U.S.

Nafamostat's potential advantages include its anticoagulant and anti-inflammatory properties as well as prospective antiviral applications. The ability of nafamostat to provide a rapid response with minimal side effects positions it as a candidate for patients who cannot tolerate heparin, the existing FDA-approved standard in CRRT settings. The complexities and risks associated with heparin and citrate, the only other solution being used, have highlighted the necessity for safer alternatives in managing anticoagulation.

The NEPHRO CRRT Study

The NEPHRO CRRT study aims to evaluate the effectiveness of Niyad in comparison to placebo in a double-blinded trial across U.S. hospital intensive care units. The research will enroll 70 adults undergoing renal therapy and is designed to assess multiple endpoints, including the mean post-filter activated clotting time. This rigorous study is poised to provide valuable data regarding the practical application of Niyad and its efficacy compared to current standard treatments.

Expert Profiles

Dr. Blaithin McMahon, PhD, MBBCh

Dr. McMahon serves as an Associate Professor of Medicine, specializing in nephrology. Her extensive background and contributions to the field, especially in Acute Kidney Injury (AKI), underscore her authority in this area. With over 50 published papers, her insights will be instrumental in highlighting the clinical applications of Niyad.

Dr. Joao Teixeira, MD

As an Associate Professor at UNM, Dr. Teixeira brings a wealth of experience from his role in inpatient nephrology and critical care. His focus across the intersection of nephrology and critical care will enhance the discussion on the clinical relevance of Niyad in the context of CRRT and patient safety.

Registration and Participation

Participants interested in insight into the latest developments in CRRT and anticoagulation management are encouraged to register for the event. Following the presentations, a live question-and-answer session will allow for engagement between attendees and the presenting experts.

Overall, this event promises to be a pivotal moment in understanding the advancements brought forward by Talphera, operating at the forefront of renal therapy innovation.

For additional details and to register, please visit the official Talphera website.

About Talphera, Inc.

Talphera is committed to developing innovative therapies for use in medically supervised environments, with Niyad being a hallmark of their therapeutic offerings. Through rigorous clinical studies and collaborations, their aim is to enhance treatment safety and efficiency for delicate patient populations worldwide.